Advances in stem cells, induced pluripotent stem cells, and engineered cells: Delivery vehicles for anti-glioma therapy

Expert Opinion on Drug Delivery

Volumn 11, Issue 11, 2014, Pages 1733-1746

  Young, Jacob S ^a   Morshed, Ramin A ^a   Kim, Julius W ^b   Balyasnikova, Irina V ^b   Ahmed, Atique U ^b   Lesniak, MacIej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cell carriers; Cell delivered cancer therapy; Engineered cells; Gene therapy; Glioma; Immunotherapy; Induced pluripotent stem cells; Nanoparticles; Oncolytic virotherapy; Stem cells; Targeted drug delivery

Indexed keywords

CANCER ANTIBODY; NANOPARTICLE; ONCOLYTIC VIRUS; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; DRUG CARRIER;

CANCER STEM CELL; CELL ENGINEERING; CELL MIGRATION; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; EMBRYONIC STEM CELL; GLIOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MULTIPOTENT STEM CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; TROPISM; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL THERAPY; BRAIN NEOPLASMS; PATHOLOGY; PROCEDURES; STEM CELL;

ANIMALS; BRAIN NEOPLASMS; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELLS;

EID: 84911477643     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.937420     Document Type: Review

References (127)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507
2. Theeler BJ, Groves MD. High-grade gliomas. Curr Treat Options Neurol 2011;13(4):386-99
3. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989;16(6):1405-9
4. Tobias A, Ahmed A, Moon KS, Lesniak MS. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry 2013;84(2):213-22
5. Perry J, Chambers A, Spithoff K, Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol (Toronto, Ont) 2007;14(5):189-94
6. Hu YL, Fu YH, Tabata Y, Gao JQ. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 2010;147(2):154-62
7. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007;211(1):27-35
8. Binello E, Germano IM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol 2012;14(3):256-65
9. Kim SU. Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev 2007;29(4):193-201
10. Aboody K, Capela A, Niazi N, et al. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 2011;70(4):597-613
11. Auffinger B, Thaci B, Nigam P, et al. New therapeutic approaches for malignant glioma: in search of the Rosetta stone. F1000 Med Rep 2012;4:18
12. Moniri MR, Sun XY, Rayat J, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther 2012;19(9):652-8
13. Menon LG, Picinich S, Koneru R, et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 2007;25(2):520-8
14. Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009;27(10):2614-23
15. Loebinger MR, Kyrtatos PG, Turmaine M, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 2009;69(23):8862-7
16. Gutova M, Najbauer J, Frank RT, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008;26(6):1406-13
17. An JH, Lee SY, Jeon JY, et al. Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res 2009;8(6):2873-81
18. Zhao D, Najbauer J, Garcia E, et al. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 2008;6(12):1819-29
19. Ziu M, Schmidt NO, Cargioli TG, et al. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 2006;79(2):125-33
20. Lee SY, Kim JM, Cho SY, et al. TIMP-1 modulates chemotaxis of human neural stem cells through CD63 and integrin signaling. Biochem J 2014;459(3):565-76
21. Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15(10):730-8
22. Kim SM, Kim DS, Jeong CH, et al. CXC chemokine receptor 1 enhances the ability of human umbilical cord bloodderived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys Res Commun 2011;407(4):741-6
23. Liu L, Eckert MA, Riazifar H, et al. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier Stem Cells Int 2013;2013:435093
24. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000;97(23):12846-51
25. Porada CD, Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 2010;62(12):1156-66
26. Marigo I, Dazzi F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 2011;33(6):593-602
27. Prevosto C, Zancolli M, Canevali P, et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007;92(7):881-8
28. Li YP, Paczesny S, Lauret E, et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008;180(3):1598-608
29. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005;12(1):47-57
30. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107(1):367-72
31. Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther 2010;12(5):546-52
32. Wei J, Wang F, Kong LY, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013;73(13):3913-26
33. Tian C, Ambroz RJ, Sun L, et al. Direct conversion of dermal fibroblasts into neural progenitor cells by a novel cocktail of defined factors. Curr Mol Med 2012;12(2):126-37
34. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-76
35. Ohi Y, Qin H, Hong C, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 2011;13(5):541-9
36. Maherali N, Sridharan R, Xie W, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007;1(1):55-70
37. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448(7151):318-24
38. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318(5858):1917-20
39. Zhou T, Benda C, Duzinger S, et al. Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol 2011;22(7):1221-8
40. Yamanaka S. A fresh look at iPS cells. Cell 2009;137(1):13-17
41. Kim JB, Sebastiano V, Wu G, et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009;136(3):411-19
42. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322(5903):945-9
43. Lee EX, Lam DH, Wu C, et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 2011;8(5):1515-24
44. Sanchez L, Gutierrez-Aranda I, Ligero G, et al. Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and antiinflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells 2011;29(2):251-62
45. Koizumi S, Gu C, Amano S, et al. Migration of mouse-induced pluripotent stem cells to glioma-conditioned medium is mediated by tumor-associated specific growth factors. Oncol Lett 2011;2(2):283-8
46. Yang J, Lam DH, Goh SS, et al. Tumor tropism of intravenously injected humaninduced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells 2012;30(5):1021-9
47. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011;474(7350):212-15
48. Guha P, Morgan JW, Mostoslavsky G, et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013;12(4):407-12
49. Balyasnikova IV, Ferguson SD, Han Y, et al. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett 2011;310(2):148-59
50. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27(9):2320-30
51. Lorico A, Mercapide J, Solodushko V, et al. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Ther 2008;15(9):605-15
52. van Eekelen M, Sasportas LS, Kasmieh R, et al. Human stem cells expressing novel TSP-1 variant have antiangiogenic effect on brain tumors. Oncogene 2010;29(22):3185-95
53. Kim SK, Cargioli TG, Machluf M, et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res 2005;11(16):5965-70
54. Lopez-Ornelas A, Vergara P, Segovia J. Neural stem cells producing an inducible and soluble form of Gas1 target and inhibit intracranial glioma growth. Cytotherapy 2014;16(7):1011-23
55. Yang ZS, Tang XJ, Guo XR, et al. Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. OncoTargets Ther 2014;7:441-6
56. Yuan X, Hu J, Belladonna ML, et al. Interleukin-23-expressing bone marrowderived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 2006;66(5):2630-8
57. Gunnarsson S, Bexell D, Svensson A, et al. Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma. J Neuroimmunol 2010;218(1-2):140-4
58. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11(14):1155-64
59. Xu G, Jiang XD, Xu Y, et al. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 2009;33(4):466-74
60. Ren C, Kumar S, Chanda D, et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008;15(21):1446-53
61. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65(8):3307-18
62. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000;6(4):447-50
63. Ehtesham M, Kabos P, Kabosova A, et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002;62(20):5657-63
64. Levy O, Zhao W, Mortensen LJ, et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013;122(14):e23-32
65. Fei S, Qi X, Kedong S, et al. The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J Cancer Res Clin Oncol 2012;138(2):347-57
66. Danks MK, Yoon KJ, Bush RA, et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007;67(1):22-5
67. Choi SA, Lee JY, Wang KC, et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer 2012;48(1):129-37
68. Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med 2013;5(184):184ra59
69. Metz MZ, Gutova M, Lacey SF, et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med 2013;2(12):983-92
70. Li S, Tokuyama T, Yamamoto J, et al. Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncology 2005;69(6):503-8
71. Rath P, Shi H, Maruniak JA, et al. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr Stem Cell Res Ther 2009;4(1):44-9
72. Alvarez CV, Garcia-Lavandeira M, Garcia-Rendueles ME, et al. Defining stem cell types: understanding the therapeutic potential of ESCs, ASCs, and iPS cells. J Mol Endocrinol 2012;49(2):R89-111
73. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J 2012;18(1):69-81
74. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14(5):1310-16
75. Josiah DT, Zhu D, Dreher F, et al. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther 2010;18(2):377-85
76. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009;16(2):262-78
77. Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26(3):831-41
78. Thaci B, Ahmed AU, Ulasov IV, et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther 2012;19(6):431-42
79. Xia X, Ji T, Chen P, et al. Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors. Mol Cancer 2011;10:134
80. Kranzler J, Tyler MA, Sonabend AM, et al. Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Curr Gene Ther 2009;9(5):389-95
81. Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Bio Ther 2007;6(5):679-85
82. Ahmed AU, Thaci B, Tobias AL, et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 2013;105(13):968-77
83. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007;99(18):1410-14
84. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009;69(23):8932-40
85. Auffinger B, Morshed R, Tobias A, et al. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma Oncotarget 2013;4(3):378-96
86. Roger M, Clavreul A, Venier-Julienne MC, et al. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011;32(8):2106-16.
87. Cheng H, Kastrup CJ, Ramanathan R, et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 2010;4(2):625-31
88. Li L, Guan Y, Liu H, et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 2011;5(9):7462-70
89. Gao Z, Zhang L, Hu J, Sun Y. Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles. Nanomedicine 2013;9(2):174-84
90. Cheng Y, Morshed R, Cheng SH, et al. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small 2013;9(24):4123-9
91. Schnarr K, Mooney R, Weng Y, et al. Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. Adv Healthc Mater 2013;2(7):976-82
92. Roger M, Clavreul A, Venier-Julienne MC, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010;31(32):8393-401
93. Roger M, Clavreul A, Huynh NT, et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 2012;423(1):63-8
94. Dai T, Yang E, Sun Y, et al. Preparation and drug release mechanism of CTSTAX-NP-MSCs drug delivery system. Int J Pharm 2013;456(1):186-94
95. Cheng Y, Morshed RA, Auffinger B, et al. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev 2014;66C:42-57
96. Compte M, Cuesta AM, Sanchez-Martin D, et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009;27(3):753-60
97. Frank RT, Najbauer J, Aboody KS. Concise review: stem cells as an emerging platform for antibody therapy of cancer. Stem Cells 2010;28(11):2084-7
98. Frank RT, Edmiston M, Kendall SE, et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One 2009;4(12):e8314
99. Balyasnikova IV, Ferguson SD, Sengupta S, et al. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One 2010;5(3):e9750
100. Kim SM, Woo JS, Jeong CH, et al. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med 2014;3(2):172-82
101. Tobias AL, Thaci B, Auffinger B, et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med 2013;2(9):655-66
102. Kim SM, Oh JH, Park SA, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010;28(12):2217-28
103. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000;97(5):2208-13
104. Heiber JF, Barber GN. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol 2011;85(20):10440-50
105. Gutova M, Frank JA, D'Apuzzo M, et al. Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl Med 2013;2(10):766-75
106. Auriat AM, Nichol H, Kelly M, Guzman R. Neural stem cell mapping with high-resolution rapid-scanning X-ray fluorescence imaging. Cell-Based Therapies in Stroke: Springer, Heiidelberg, New York, Dordrecht, and London; 2013 p. 127-36
107. Balyasnikova IV, Prasol MS, Ferguson SD, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther 2014;22(1):140-8
108. Varma NR, Janic B, Iskander AS, et al. Endothelial progenitor cells (EPCs) as gene carrier system for rat model of human glioma. PLoS One 2012;7(1):e30310
109. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449(7162):557-63
110. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008;17(3):463-73
111. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6(2):e1000029
112. Sato H, Kuwashima N, Sakaida T, et al. Epidermal growth factor receptortransfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 2005;12(9):757-68
113. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15(10):739-52
114. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011;11(4):268-77
115. Miura K, Okada Y, Aoi T, et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009;27(8):743-5 1
116. Wang L, Wang L, Huang W, et al. Generation of integration-free neural progenitor cells from cells in human urine. Nat Methods 2013;10(1):84-9
117. Ahmed AU, Tyler MA, Thaci B, et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm 2011;8(5):1559-72
118. Pendleton C, Li Q, Chesler DA, et al. Mesenchymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tropism towards gliomas. PLoS One 2013;8(3):e58198
119. Auvinen P, Tammi R, Kosma VM, et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 2013;132(3):531-9
120. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459(7249):1005-9
121. Kauer TM, Figueiredo JL, Hingtgen S, Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci 2012;15(2):197-204
122. Kim CK, Ahmed AU, Auffinger B, et al. N-acetylcysteine amide augments the therapeutic effect of neural stem cellbased antiglioma oncolytic virotherapy. Mol Ther 2013;21(11):2063-73 1
123. Yuan Q, Zhang Y, Chen T, et al. Photon-manipulated drug release from a mesoporous nanocontainer controlled by azobenzene-modified nucleic acid. ACS Nano 2012;6(7):6337-44 1
124. Tate CC, Shear DA, Tate MC, et al. Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain. J Tissue Eng Regen Med 2009;3(3):208-17 1
125. Bensaid W, Triffitt JT, Blanchat C, et al. A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. Biomaterials 2003;24(14):2497-502 1
126. Lin D, Najbauer J, Salvaterra PM, et al. Novel method for visualizing and modeling the spatial distribution of neural stem cells within intracranial glioma. Neuroimage 2007;37:Suppl 1:S18-26 1
127. Ito S, Natsume A, Shimato S, et al. Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer Gene Ther 2010;17(5):299-306